Does the media favor DRUG or ARDX?

In the previous week, Ardelyx had 30 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 36 mentions for Ardelyx and 6 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.62 beat Ardelyx's score of 0.13 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 3 Very Positive mention(s) 0 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, HELP or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is HELP or DRUG more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Bright Minds Biosciences N/A -12.46% -12.30%

Does the media favor HELP or DRUG?

In the previous week, Bright Minds Biosciences had 1 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Bright Minds Biosciences and 5 mentions for Cybin. Cybin's average media sentiment score of 0.68 beat Bright Minds Biosciences' score of 0.62 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ACHV or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is ACHV or DRUG more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -511.12% -82.35% Bright Minds Biosciences N/A -12.46% -12.30%

Does the media favor ACHV or DRUG?

In the previous week, Achieve Life Sciences had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 9 mentions for Achieve Life Sciences and 6 mentions for Bright Minds Biosciences. Achieve Life Sciences' average media sentiment score of 0.73 beat Bright Minds Biosciences' score of 0.62 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DRUG or ZVRA?

In the previous week, Zevra Therapeutics had 8 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 14 mentions for Zevra Therapeutics and 6 mentions for Bright Minds Biosciences. Zevra Therapeutics' average media sentiment score of 0.84 beat Bright Minds Biosciences' score of 0.62 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bright Minds Biosciences (DRUG) Competitors

$23.45 +0.84 (+3.72%)

Closing price 11/11/2026 04:00 PM Eastern

Extended Trading

$23.37 -0.08 (-0.34%)

As of 11/11/2026 07:43 PM Eastern

Compare

DRUG vs. COLL, ARDX, HELP, ACHV, and ZVRA

Should you buy Bright Minds Biosciences stock or one of its competitors? Bright Minds Biosciences's main competitors and comparable companies include Collegium Pharmaceutical (COLL), Ardelyx (ARDX), Cybin (HELP), Achieve Life Sciences (ACHV), and Zevra Therapeutics (ZVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bright Minds Biosciences compare to Collegium Pharmaceutical?

Bright Minds Biosciences (NASDAQ:DRUG) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

40.5% of Bright Minds Biosciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Collegium Pharmaceutical has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A
Collegium Pharmaceutical	$780.57M	0.99	$62.87M	$1.00	24.81

Bright Minds Biosciences presently has a consensus price target of $126.29, indicating a potential upside of 438.53%. Collegium Pharmaceutical has a consensus price target of $44.88, indicating a potential upside of 80.87%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Bright Minds Biosciences is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Bright Minds Biosciences has a beta of -5.11, meaning that its share price is 611% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 18 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 24 mentions for Collegium Pharmaceutical and 6 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.62 beat Collegium Pharmaceutical's score of 0.32 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a net margin of 4.68% compared to Bright Minds Biosciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 85.14% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-12.46%	-12.30%
Collegium Pharmaceutical	4.68%	85.14%	13.80%

Summary

Collegium Pharmaceutical beats Bright Minds Biosciences on 9 of the 15 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Ardelyx?

Bright Minds Biosciences (NASDAQ:DRUG) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Ardelyx had 30 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 36 mentions for Ardelyx and 6 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.62 beat Ardelyx's score of 0.13 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	3 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bright Minds Biosciences presently has a consensus price target of $126.29, indicating a potential upside of 438.53%. Ardelyx has a consensus price target of $13.60, indicating a potential upside of 334.50%. Given Bright Minds Biosciences' higher probable upside, research analysts plainly believe Bright Minds Biosciences is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Ardelyx	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Bright Minds Biosciences has a beta of -5.11, meaning that its stock price is 611% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Bright Minds Biosciences has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A
Ardelyx	$407.32M	1.93	-$61.60M	-$0.22	N/A

Bright Minds Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -11.85%. Bright Minds Biosciences' return on equity of -12.46% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-12.46%	-12.30%
Ardelyx	-11.85%	-35.30%	-10.23%

Summary

Bright Minds Biosciences and Ardelyx tied by winning 7 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Cybin?

Cybin (NASDAQ:HELP) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Cybin has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.11, suggesting that its stock price is 611% less volatile than the broader market.

Cybin presently has a consensus target price of $47.33, indicating a potential upside of 404.08%. Bright Minds Biosciences has a consensus target price of $126.29, indicating a potential upside of 438.53%. Given Bright Minds Biosciences' higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Cybin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Bright Minds Biosciences had 1 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Bright Minds Biosciences and 5 mentions for Cybin. Cybin's average media sentiment score of 0.68 beat Bright Minds Biosciences' score of 0.62 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

17.9% of Cybin shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bright Minds Biosciences' return on equity of -12.46% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Summary

Bright Minds Biosciences beats Cybin on 10 of the 13 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Achieve Life Sciences?

Achieve Life Sciences (NASDAQ:ACHV) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Achieve Life Sciences has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.11, suggesting that its stock price is 611% less volatile than the broader market.

Bright Minds Biosciences' return on equity of -12.46% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

In the previous week, Achieve Life Sciences had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 9 mentions for Achieve Life Sciences and 6 mentions for Bright Minds Biosciences. Achieve Life Sciences' average media sentiment score of 0.73 beat Bright Minds Biosciences' score of 0.62 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Achieve Life Sciences currently has a consensus price target of $15.50, indicating a potential upside of 131.17%. Bright Minds Biosciences has a consensus price target of $126.29, indicating a potential upside of 438.53%. Given Bright Minds Biosciences' higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Achieve Life Sciences and Bright Minds Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Zevra Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Zevra Therapeutics has a net margin of 52.80% compared to Bright Minds Biosciences' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.64% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-12.46%	-12.30%
Zevra Therapeutics	52.80%	54.64%	37.84%

Bright Minds Biosciences currently has a consensus target price of $126.29, indicating a potential upside of 438.53%. Zevra Therapeutics has a consensus target price of $27.14, indicating a potential upside of 129.05%. Given Bright Minds Biosciences' higher possible upside, equities analysts clearly believe Bright Minds Biosciences is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bright Minds Biosciences has a beta of -5.11, indicating that its stock price is 611% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A
Zevra Therapeutics	$147.76M	4.77	$83.23M	$1.19	9.96

In the previous week, Zevra Therapeutics had 8 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 14 mentions for Zevra Therapeutics and 6 mentions for Bright Minds Biosciences. Zevra Therapeutics' average media sentiment score of 0.84 beat Bright Minds Biosciences' score of 0.62 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zevra Therapeutics beats Bright Minds Biosciences on 11 of the 14 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$220.04M	$13.79B	$7.89B	$12.02B
Dividend Yield	N/A	2.55%	2.45%	4.45%
P/E Ratio	-11.27	25.99	34.27	29.14
Price / Sales	N/A	8.07	8.79	5.82
Price / Cash	N/A	15.68	22.08	22.50
Price / Book	2.82	5.04	4.45	3.80
Net Income	-$8.74M	$2.87B	$3.50B	$390.04M
7 Day Performance	13.29%	2.86%	2.54%	3.40%
1 Month Performance	-56.58%	-4.51%	-3.20%	-5.35%
1 Year Performance	-61.01%	-6.37%	1.02%	-5.92%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	3.014 of 5 stars	$23.45 +3.7%	$126.29 +438.5%	-60.4%	$220.04M	N/A	N/A	25
COLL Collegium Pharmaceutical	3.853 of 5 stars	$23.73 +0.2%	$48.71 +105.3%	-44.7%	$772.65M	$780.57M	19.14	423	Earnings Report Analyst Upgrade
ARDX Ardelyx	3.5879 of 5 stars	$3.03 flat	$13.90 +358.7%	-48.9%	$755.05M	$407.32M	N/A	489	Trending News Analyst Forecast Options Volume
HELP Cybin	4.5261 of 5 stars	$9.03 +2.6%	$47.33 +424.2%	N/A	$720.68M	N/A	N/A	100	Gap Up
ACHV Achieve Life Sciences	2.664 of 5 stars	$6.73 +1.8%	$15.50 +130.3%	+40.6%	$692.53M	N/A	N/A	28	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. COLL, ARDX, HELP, ACHV, and ZVRA

How does Bright Minds Biosciences compare to Collegium Pharmaceutical?

Summary

How does Bright Minds Biosciences compare to Ardelyx?

Summary

How does Bright Minds Biosciences compare to Cybin?

Summary

How does Bright Minds Biosciences compare to Achieve Life Sciences?

Summary

How does Bright Minds Biosciences compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. COLL, ARDX, HELP, ACHV, and ZVRA

How does Bright Minds Biosciences compare to Collegium Pharmaceutical?

Do institutionals and insiders believe in DRUG or COLL?

Which has preferable valuation & earnings, DRUG or COLL?

Do analysts recommend DRUG or COLL?

Which has more volatility & risk, DRUG or COLL?

Does the media prefer DRUG or COLL?

Is DRUG or COLL more profitable?

Summary

How does Bright Minds Biosciences compare to Ardelyx?

Does the media favor DRUG or ARDX?

Do insiders and institutionals believe in DRUG or ARDX?

Do analysts recommend DRUG or ARDX?

Which has more volatility and risk, DRUG or ARDX?

Which has preferable earnings & valuation, DRUG or ARDX?

Is DRUG or ARDX more profitable?

Summary

How does Bright Minds Biosciences compare to Cybin?

Which has more risk and volatility, HELP or DRUG?

Do analysts recommend HELP or DRUG?

Does the media favor HELP or DRUG?

Which has preferable earnings and valuation, HELP or DRUG?

Do institutionals & insiders believe in HELP or DRUG?

Is HELP or DRUG more profitable?

Summary

How does Bright Minds Biosciences compare to Achieve Life Sciences?

Do institutionals & insiders believe in ACHV or DRUG?

Which has better valuation & earnings, ACHV or DRUG?

Which has more risk & volatility, ACHV or DRUG?

Is ACHV or DRUG more profitable?

Does the media favor ACHV or DRUG?

Do analysts recommend ACHV or DRUG?

Summary

How does Bright Minds Biosciences compare to Zevra Therapeutics?

Is DRUG or ZVRA more profitable?

Do analysts rate DRUG or ZVRA?

Do insiders & institutionals hold more shares of DRUG or ZVRA?

Which has more risk and volatility, DRUG or ZVRA?

Which has stronger earnings and valuation, DRUG or ZVRA?

Does the media favor DRUG or ZVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools